Compare WKHS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | ICU |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 15.9M |
| IPO Year | N/A | N/A |
| Metric | WKHS | ICU |
|---|---|---|
| Price | $5.38 | $2.26 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 225.4K | 112.5K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $881,000.00 |
| Revenue This Year | $92.70 | $691.85 |
| Revenue Next Year | $34.00 | $64.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 16.73 | ★ 1195.59 |
| 52 Week Low | $5.01 | $2.20 |
| 52 Week High | $118.50 | $30.70 |
| Indicator | WKHS | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 82.71 |
| Support Level | $5.20 | $2.40 |
| Resistance Level | $6.00 | $2.81 |
| Average True Range (ATR) | 0.40 | 0.10 |
| MACD | -0.18 | 0.25 |
| Stochastic Oscillator | 35.35 | 79.93 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.